文献速递主动脉疾病

感染性自体主动脉瘤原位重建十五年单中心经验

Fifteen-year, single-center experience with in situ reconstruction for infected native aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2021-09-30

该单中心回顾性研究纳入2005至2020年65例感染性自体主动脉瘤患者,评估原位血运重建(开放手术或腔内)的生存与免于再感染情况。30天死亡率为6.2%,住院死亡率为10.8%,估计1年和5年生存率分别为79.7%和67.4%。多因素分析显示未控制脓毒症、动脉瘤快速扩张和梭形动脉瘤与住院死亡率升高相关,手术时间延长与再感染风险增加相关。

要点

  • 感染性自体主动脉瘤行原位重建的30天死亡率为6.2%,住院死亡率为10.8%。
  • 估计5年生存率为67.4%,5年免于再感染率为79.4%。
  • 未控制脓毒症、动脉瘤快速扩张和梭形动脉瘤与住院死亡率升高独立相关。

核心结论

  • 选择性使用原位血运重建联合开放手术及针对性抗菌治疗在感染性自体主动脉瘤中效果尚可。
  • 仍需更大规模前瞻性多中心研究确认血管移植物选择及EVAR作为桥接或 definitive 治疗的角色。

研究设计与样本

  • 回顾性单中心研究,纳入2005年1月至2020年12月接受原位血运重建的感染性自体主动脉瘤患者65例。
  • 诊断需满足临床表现、实验室结果、影像学表现和术中发现中至少两项标准。
  • 主要终点为30天死亡率,次要终点包括住院死亡率、估计生存率、通畅率和免于再感染率。

主要发现

  • 65例患者中男性53例(81.5%),中位年龄69.0岁(IQR 61.5-75.0岁),免疫功能低下31例(47.7%),有症状60例(92.3%),破裂32例(49.2%)。
  • 最常见部位为肾下型(39例,60.0%),55例(84.6%)行初次开放手术原位重建,3例(4.6%)以EVAR桥接开放手术,8例(12.3%)以EVAR为 definitive 治疗。
  • 30天死亡4例(6.2%),住院死亡7例(10.8%),中位随访33.5个月(IQR 13.6-62.3个月)。
  • 估计1年和5年生存率分别为79.7%(95%CI 67.6%-87.7%)和67.4%(95%CI 51.2%-79.3%),相应免于再感染率分别为92.5%(95%CI 81.1%-97.1%)和79.4%(95%CI 59.1%-90.3%)。
  • 多因素分析显示住院死亡率随未控制脓毒症(P < .0001)、快速扩张动脉瘤(P = .008)和梭形动脉瘤(P = .03)升高,再感染发生率随手术时间延长升高(P = .009)。

临床怎么用

  • 对感染性自体主动脉瘤患者,可选择性采用原位重建联合开放手术及针对性抗菌治疗。
  • 术前应关注未控制脓毒症、动脉瘤快速扩张和梭形形态以评估住院死亡风险。
  • 缩短手术时间可能有助于降低再感染风险。

局限性

  • 回顾性单中心研究,样本量有限。
  • 需要更大规模前瞻性多中心研究确认 findings 及最佳血管移植物和EVAR角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of the present study was to evaluate the survival and freedom from reinfection for patients with infected native aortic aneurysms (INAAs) treated with in situ revascularization (ISR), using either open surgical repair (OSR) or endovascular aneurysm repair (EVAR), and to identify the predictors of outcome. METHODS: Patients with INAAs who had undergone ISR from January 2005 to December 2020 were included in the present retrospective single-center study. The diagnosis of INAAs required a combination of two or more of the following criteria: (1) clinical presentation, (2) laboratory results, (3) imaging findings, and (4) intraoperative findings. The primary endpoint was 30-day mortality. The secondary endpoints were in-hospital mortality, estimated survival, patency, and freedom from reinfection using the Kaplan-Meier method. The predictive factors for adverse outcomes were evaluated using the Mann-Whitney U test or the Fisher exact test and multivariate regression analysis. RESULTS: A total of 65 patients (53 men [81.5%]; median age, 69.0 years; interquartile range, 61.5-75.0 years) were included, 31 (47.7%) were immunocompromised, 60 were symptomatic (92.3%), and 32 (49.2%) had presented with rupture, including 3 aortocaval fistulas (4.6%) and 12 aortoenteric fistulas (18.5%). The most common location was infrarenal (n = 39; 60.0%). Of the 65 patients, 55 (84.6%) had undergone primary OSR with ISR, 3 (4.6%) had required EVAR as a bridge to OSR, and 8 (12.3%) had undergone EVAR as definitive treatment. The approach was a midline laparotomy for 44 patients (67.7%), mostly followed by reconstruction and aortic-aortic bypass (n = 28; 40.6%) and the use of a silver and triclosan Dacron graft (n = 30; 43.5%). Causative organisms were identified in 55 patients (84.6%). The 30-day and in-hospital mortality rates were 6.2% (n = 4) and 10.8% (n = 7). The median follow-up was 33.5 months (interquartile range, 13.6-62.3 months). The estimated 1- and 5-year survival rates were 79.7% (95% confidence interval [CI], 67.6%-87.7%) and 67.4% (95% CI, 51.2%-79.3%). The corresponding freedom from reinfection rates were 92.5% (95% CI, 81.1%-97.1%) and 79.4% (95% CI, 59.1%-90.3%). On multivariate analysis, in-hospital mortality increased with uncontrolled sepsis (P < .0001), rapidly expanding aneurysms (P = .008), and fusiform aneurysms (P = .03). The incidence of reinfection increased with longer operating times (P = .009). CONCLUSIONS: The selective use of ISR and OSR combined with targeted antimicrobial therapy functioned reasonably well in the treatment of INAAs, although larger, prospective, multicenter studies with appropriately powered comparative cohorts are necessary to confirm our findings and to determine the best vascular substitute and precise role of EVAR as a bridge to OSR or definitive treatment.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Berard X, Battut AS, Puges M, et al. Fifteen-year, single-center experience with in situ reconstruction for infected native aortic aneurysms. J Vasc Surg. 2021. PMID: 34600030. doi:10.1016/j.jvs.2021.08.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。